

Tsuneo Saga

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1341976/publications.pdf>

Version: 2024-02-01

49
papers

1,474
citations

394421

19
h-index

315739

38
g-index

51
all docs

51
docs citations

51
times ranked

1431
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Value of Positron Emission Tomography with FDG for Recurrent Ovarian Cancer. American Journal of Roentgenology, 2001, 176, 1449-1454.	2.2	144
2	3D-micro-MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with reference to their pharmacokinetic properties. Magnetic Resonance in Medicine, 2001, 45, 454-460.	3.0	143
3	Pharmacokinetics and enhancement patterns of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores. Magnetic Resonance in Medicine, 2001, 46, 1169-1173.	3.0	127
4	Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer. Annals of Nuclear Medicine, 2003, 17, 197-203.	2.2	109
5	FDG-PET of autoimmune-related pancreatitis: preliminary results. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 1835-1838.	2.1	97
6	Micro-MR angiography of normal and intratumoral vessels in mice using dedicated intravascular MR contrast agents with high generation of polyamidoamine dendrimer core: Reference to pharmacokinetic properties of dendrimer-based MR contrast agents. Journal of Magnetic Resonance Imaging, 2001, 14, 705-713.	3.4	86
7	Evaluation of Primary Brain Tumors With FLT-PET: Usefulness and Limitations. Clinical Nuclear Medicine, 2006, 31, 774-780.	1.3	86
8	Characterization of FDG-PET images after stereotactic body radiation therapy for lung cancer. Radiotherapy and Oncology, 2010, 97, 200-204.	0.6	71
9	¹⁸ F-FDG and ¹¹ C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy. Annals of Nuclear Medicine, 2004, 18, 669-674.	2.2	60
10	3D MR angiography of intratumoral vasculature using a novel macromolecular MR contrast agent. Magnetic Resonance in Medicine, 2001, 46, 579-585.	3.0	45
11	Discovery of an uncovered region in fibrin clots and its clinical significance. Scientific Reports, 2013, 3, 2604.	3.3	44
12	Novel intravascular macromolecular MRI contrast agent with generation-4 polyamidoamine dendrimer core: Accelerated renal excretion with coinjection of lysine. Magnetic Resonance in Medicine, 2001, 46, 457-464.	3.0	41
13	Evaluation of ⁸⁹ Zr-Labeled Human Anti-CD147 Monoclonal Antibody as a Positron Emission Tomography Probe in a Mouse Model of Pancreatic Cancer. PLoS ONE, 2013, 8, e61230.	2.5	34
14	Evaluation of Efficacy of Radioimmunotherapy with ⁹⁰ Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models. PLoS ONE, 2015, 10, e0123761.	2.5	30
15	Therapeutic Efficacy of C-Kit-Targeted Radioimmunotherapy Using ⁹⁰ Y-Labeled Anti-C-Kit Antibodies in a Mouse Model of Small Cell Lung Cancer. PLoS ONE, 2013, 8, e59248.	2.5	27
16	ZDHHC8 knockdown enhances radiosensitivity and suppresses tumor growth in a mesothelioma mouse model. Cancer Science, 2012, 103, 203-209.	3.9	26
17	C-kit-targeted imaging of gastrointestinal stromal tumor using radiolabeled anti-c-kit monoclonal antibody in a mouse tumor model. Nuclear Medicine and Biology, 2010, 37, 179-187.	0.6	25
18	Development of Antibody-Drug Conjugates Using DDS and Molecular Imaging. Bioengineering, 2017, 4, 78.	3.5	23

#	ARTICLE	IF	CITATIONS
19	Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts. <i>Nuclear Medicine and Biology</i> , 2009, 36, 379-388.	0.6	21
20	Imaging of intraperitoneal tumors with technetium-99m GSA. <i>Annals of Nuclear Medicine</i> , 1998, 12, 115-118.	2.2	20
21	PET/CT with ^3H -deoxy- ^3H -[18F]fluorothymidine for lung cancer patients receiving carbon-ion radiotherapy. <i>Nuclear Medicine Communications</i> , 2011, 32, 348-355.	1.1	18
22	Clinical value of FDG-PET for preoperative evaluation of endometrial cancer. <i>Annals of Nuclear Medicine</i> , 2011, 25, 269-275.	2.2	18
23	Efficacy Evaluation of Combination Treatment Using Gemcitabine and Radioimmunotherapy with ^{90}Y -Labeled Fully Human Anti-CD147 Monoclonal Antibody O59-053 in a BxPC-3 Xenograft Mouse Model of Refractory Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2979.	4.1	18
24	Prognostic Value of Quantitative Parameters of ^{18}F -FDG PET/CT for Patients With Angiosarcoma. <i>American Journal of Roentgenology</i> , 2020, 214, 649-657.	2.2	16
25	Radioimmunotherapy of pancreatic cancer xenografts in nude mice using ^{90}Y -labeled anti- $\alpha_6\beta_4$ integrin antibody. <i>Oncotarget</i> , 2016, 7, 38835-38844.	1.8	15
26	Therapeutic efficacy evaluation of radioimmunotherapy with ^{90}Y -labeled anti- $\alpha_6\beta_4$ integrin antibody NZ-12 for mesothelioma. <i>Cancer Science</i> , 2019, 110, 1653-1664.	3.9	13
27	First-in-Human Evaluation of Positron Emission Tomography/Computed Tomography With [18F]FB(ePEG12)12-Exendin-4: A Phase 1 Clinical Study Targeting GLP-1 Receptor Expression Cells in Pancreas. <i>Frontiers in Endocrinology</i> , 2021, 12, 717101.	3.5	12
28	Deep Learning-based Noise Reduction for Fast Volume Diffusion Tensor Imaging: Assessing the Noise Reduction Effect and Reliability of Diffusion Metrics. <i>Magnetic Resonance in Medical Sciences</i> , 2021, 20, 450-456.	2.0	11
29	Radioimmunotherapy for Liver Micrometastases in Mice: Pharmacokinetics, Dose Estimation, and Long-term Effect. <i>Japanese Journal of Cancer Research</i> , 1999, 90, 342-348.	1.7	10
30	Initial evaluation of PET / CT with ^{18}F -FSU α_880 targeting prostate-specific membrane antigen in prostate cancer patients. <i>Cancer Science</i> , 2019, 110, 742-750.	3.9	10
31	Prognostic utility of FDG PET/CT in advanced ovarian, fallopian and primary peritoneal high-grade serous cancer patients before and after neoadjuvant chemotherapy. <i>Annals of Nuclear Medicine</i> , 2020, 34, 128-135.	2.2	10
32	Immunoscintigraphy and Pharmacokinetics of Indium-111-labeled ZME-018 Monoclonal Antibody in Patients with Malignant Melanoma. <i>Japanese Journal of Cancer Research</i> , 1988, 79, 973-981.	1.7	9
33	Increased ^{14}C -acetate accumulation in IDH-mutated human glioblastoma: implications for detecting IDH-mutated glioblastoma with ^{11}C -acetate PET imaging. <i>Journal of Neuro-Oncology</i> , 2019, 145, 441-447.	2.9	8
34	Immunohistochemical Localization of CA130 in Fetal Tissues, and in Normal and Neoplastic Tissues of the Female Genital Tract. <i>Asia-Oceania Journal of Obstetrics and Gynaecology</i> , 1990, 16, 379-387.	0.0	7
35	Imaging of Hypoxic Tumor: Correlation between Diffusion-weighted MR Imaging and ^{18}F -fluoroazomycin Arabinoside Positron Emission Tomography in Head and Neck Carcinoma. <i>Magnetic Resonance in Medical Sciences</i> , 2020, 19, 276-281.	2.0	6
36	Effect of Circulating Antigen on Immunoscintigraphy of Ovarian Cancer Patients Using Anti-CA125 Monoclonal Antibody. <i>Japanese Journal of Cancer Research</i> , 1996, 87, 655-661.	1.7	5

#	ARTICLE	IF	CITATIONS
37	Radiolabeled Human Monoclonal Antibody 067-213 has the Potential for Noninvasive Quantification of CD73 Expression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2304.	4.1	5
38	Avidin Chase Can Reduce Myelotoxicity Associated with Radioimmunotherapy of Experimental Liver Micrometastases in Mice. <i>Japanese Journal of Cancer Research</i> , 2000, 91, 622-628.	1.7	4
39	Performance Evaluation of a Newly Developed MR-Compatible Mobile PET Scanner with Two Detector Layouts. <i>Molecular Imaging and Biology</i> , 2020, 22, 407-415.	2.6	4
40	Increased [18F]FMISO accumulation under hypoxia by multidrug-resistant protein 1 inhibitors. <i>EJNMMI Research</i> , 2021, 11, 9.	2.5	4
41	Qualitative and Quantitative Assessment of Nonlocal Means Reconstruction Algorithm in a Flexible PET Scanner. <i>American Journal of Roentgenology</i> , 2021, 216, 486-493.	2.2	3
42	Enhanced intestinal 2-deoxy-2-[¹⁸ F]fluoro-D-glucose uptake under metformin is not fully suppressed by loperamide. <i>Endocrine Regulations</i> , 2018, 52, 185-191.	1.3	2
43	Do TSH, FT3, and FT4 Impact BAT Visualization of Clinical FDG-PET/CT Images?. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-9.	0.8	2
44	Predominance and homogeneity patterns of physiological FDG accumulation in thoracic and lumbar vertebrae: suspected mechanism of "bone pseudometastasis" on FDG-PET in Japanese patients with esophageal cancer. <i>Annals of Nuclear Medicine</i> , 2020, 34, 182-191.	2.2	1
45	Clinical value of PET/CT with carbon-11 4DST in the evaluation of malignant and benign lung tumors. <i>Annals of Nuclear Medicine</i> , 2021, 35, 211-222.	2.2	1
46	Physiologically decreased F-18 fluorodeoxyglucose uptake in the lower vertebrae associated with daily drinking habit in Japanese men with alcohol flushing reaction. <i>Alcohol</i> , 2021, 95, 15-23.	1.7	1
47	Development of a novel Indium-111 radiolabeled mogamulizumab targeting CCR4 for imaging adult T-cell leukemia/lymphoma in vivo. <i>Annals of Nuclear Medicine</i> , 2022, 36, 319.	2.2	1
48	Detection efficacy of PET/CT with 18F-FSU-880 in patients with suspected recurrent prostate cancer: a prospective single-center study. <i>Annals of Nuclear Medicine</i> , 2022, 36, 302.	2.2	1
49	CAST Diagnostic Imaging. , 2019, , 289-307.		0